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Abstract
Background: The use of a balloon expandable stent valve includes balloon predilatation of the aortic stenosis
before valve deployment. The aim of the study was to see whether or not balloon predilatation is necessary in
transcatheter aortic valve replacement (TAVI).
Methods: Sixty consecutive TAVI patients were randomized to the standard procedure or to a protocol where
balloon predilatation was omitted.
Results: There were no significant differences between the groups regarding early hemodynamic results or
complication rates.
Conclusions: TAVI can be performed safely without balloon predilatation and with the same early results as
achieved with the standard procedure including balloon predilatation. The reduction in the number of pacing
periods required may be beneficial for the patient.
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Background
Transcatheter Aortic Valve Implantation (TAVI) is now
a widespread procedure and there are international
guidelines for selection of patients and for the reporting
of results [1–3]. Long- term results have so far been
convincing [4, 5] and continuous technologic and mater-
ial development has improved the technique. In many
centers the original TAVI protocol has been simplified
over the years in an attempt to reduce or avoid any risk
associated with the procedure. The standard procedure
includes predilatation of the stenotic valve with a bal-
loon before stent deployment, with at least two periods
of rapid pacing per TAVI procedure. Should the balloon
slide during inflation, additional periods of pacing are
necessary. Some patients react with slow recovery of
heart function, and we had three patients requiring re-
suscitation and temporary extracorporeal circulation in
our first 100 TAVI patients. In 2011 we started to omit
predilatation during the procedure and thereby reduced
the number of pacing periods. Of 258 TAVI patients,
predilatation was avoided in 139. The results indicated
that the procedure could be performed safely without
predilatation. As these patient groups represent two
different time periods, where a learning curve could
have interfered with outcome, we decided to do a pro-
spective randomized study including all consecutive
TAVI patients during the course of one year.
Methods
Sixty consecutive TAVI patients were randomized to
receive balloon predilatation or not. Valve-in-valve pro-
cedures and patients previously treated with balloon
dilatation were excluded. The study was approved by the
Regional Ethical Committee on Human Research, and
all patients gave informed consent for participation in
the study. They were randomized using a double
envelope system. The sealed envelope was opened just
before starting the procedure. The patients and the 1-
month follow-up cardiologist performing transesophageal
echocardiography were blinded to the randomization. The
* Correspondence: Henrik.casimir.ahn@liu.se
1Department of Cardiothoracic Surgery, University Hospital, Institution of
Medical and Health Sciences, Linkoping University, Linkoping, Sweden
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ahn et al. Journal of Cardiothoracic Surgery  (2016) 11:124 
DOI 10.1186/s13019-016-0516-x
echocardiographic evaluation of prosthetic aortic valve re-
gurgitation was performed by at least one cardiologist
with expertise in the method. Investigations were per-
formed in a key national lab where almost all TAVI cases
at our department have been operated from the start. The
VARC 2 criteria were used [3]. A bovine pericardial stent
valve (Sapien XT, Edwards Inc. Santa Ana, CA) was used
in all patients. Demographic data are shown in Table 1.
Procedure
General anesthesia and transesophageal echocardiography
(TOE) were routinely used. In the transfemoral group the
common femoral artery was punctured in the anterior
wall with ultrasound guidance. Two percutaneous closure
devices (Proglide™) were inserted prior to dilatation of the
vessel. Adequate cusp alignment was facilitated with
ultrasound-guided placement and adjustment of the image
system [6]. TOE was used to confirm correct placement
of the stent valve and to evaluate the hemodynamic result.
Contrast injection in the aortic root was performed
only when the fluoroscopic view or TOE was not good
enough for visualizing the aortic root and cusp align-
ment. In the predilatation group the balloon was intro-
duced and blown up during a period of rapid pacing
(RP). If the balloon migrated, further RP was done. The
stent valve was then positioned and deployed during one
more pacing period. In the group without balloon dilata-
tion, the valve was passed through the stenotic valve and
the stent valve deployed during one RP period.
When the transapical approach was used we regularly
passed the stenotic valve with the introducer which then
was withdrawn before stent valve deployment. In the
predilatation group a balloon catheter was introduced
through the stenosis and blown up during RP according
to the standard protocol.
Statistics
The VARC-2 endpoint definitions were used for selected
variables [3, 7, 8]. The data were prospectively saved in
the hospital’s digital data-base, and also transferred to an
Excel data-base for analysis. The study design and sam-
ple size were chosen with hemodynamic non-inferiority
as primary endpoint. Intention-to-treat analysis of data
was performed. Continuous variables were tested for
normality using the Shapiro-Wilks test. Student’s t-test
for independent samples was used to test difference be-
tween the two groups. Categorical variables were com-
pared using the chi-square test, or Fischer’s exact test
when the number of observations was very small (<5). A
p value <0,05 between the groups was regarded as sig-




Table 2 summarizes the results. There was a trend to-
wards shorter procedure time and less contrast delivery
in the no balloon dilatation (NBD) group, not reaching
statistical significance. In almost half of the patients
(27/60) no contrast was given. Vascular complications
according to the VARC 2 [3] criteria did not differ be-
tween the groups. Pericardial bleeding at the end of the
procedure occurred in 2 patients in each group. Three
were successfully treated with pericardial drainage. One
patient in the NBD group needed temporary circulatory
support, and sternotomy and myocardial suture due to
guidewire perforation. Sternotomy and myocardial su-
ture, without ECC, was performed in another NBD pa-
tient for the same reason. One patient in the balloon
dilatation (BD) group needed circulatory support over
thirty minutes after the pacing period due to low out-
put syndrome. One patient in the standard group suf-
fered from sudden severe fall in blood pressure before
pacing and balloon dilatation, and the stent valve was
quickly deployed without planned balloon dilatation
during one short period of pacing. In another planned
BD patient the balloon migrated two times during
inflation and we chose to continue without further at-
tempts. One BD patient developed moderate valvular re-
gurgitation, and due to clinical symptoms a valve-in-valve
procedure was performed one week after the initial pro-
cedure. One patient randomized to BD had sudden onset
of tachycardia with low cardiac output in association with
balloon introduction through the stenosis. We avoided
dilatation, and the stent valve was deployed without
pacing. Valve embolization occurred in one NBD patient
due to inaccurate withdrawal of the pusher before valve
deployment. The valve was stented in the decending aorta
and a new valve was adequately positioned and deployed.









Men/women (n) 14/16 16/14 ns
Age, mean (range) 83 (58–93) 81 (42–91) ns
Euroscore I 17 (2–38) 19 (4–57) ns
Euroscore II 8 (2–18) 9 (3–37) ns
STS score 7 (1–13) 6 (2–17) ns
PPM (n) 1 2 ns
Vmax m/s 4.4 (2.9–5.8) 4.3 (3.3–5.8) ns
Mean gradient mmHg 51 (21–84) 48 (29–88) ns
EOA cm2 0.6 (0.3–0.9) 0.6 (0.3–1.0) ns
STS Society of Thoracic Surgeons, PPM Permanent pacemaker, Vmax maximum
upstroke velocity, EOA effective orifice area
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Paravalvular leakage was mild or less in all patients. There
was no procedural mortality.
One-month follow-up
Data on function did not differ between the groups.
Paravalvular leak was mild or less in all patients. The
number of complications was low. One patient in the
NBF group received a permanent pacemaker due to
bradycardia. Three patients had ischemic stroke, one dis-
abling stroke in each group and a non-disabling stroke
in the BD group. There were three deaths, one due to
acute myocardial infarction in a 66 year-old man, one
due cardiac arrest in a 76 year-old man, and one due to
worsening heart failure before discharge in a 91 year-old
man. Data are summarized in Table 3.
Discussion
This study shows that it is possible to omit balloon
predilatation from the standard TAVI procedure without
affecting early outcome regarding hemodynamic results.
This is an interesting topic that has not been well docu-
mented and yet most centers have omitted pre dilatation
for the past several years. A similar conclusion has
previously been reported in non-randomized series of
patients using self-expandable stent valves and balloon-
expandable valves [9–11]. The number of rapid pacing
periods in our study was significantly reduced, and the
initial and one month hemodynamic results were similar
between the groups. The frequency of complications was
similar and there was a trend towards shorter procedural
time and less need for contrast delivery in the group
without balloon predilatation. Though the study had a
rather small number of patients, it was designed to
investigate non-inferiority and results indicate that bal-
loon predilatation is not necessary, but there was not the
power to prove if there are advantages in outcome with
this modification. We initially planned to include double
the sample size in order to evaluate outcome, and
planned for a 2-year study. After 1 year the members of
the TAVI-team were very reluctant to proceed with the
study (especially the anesthesiologists) since they consid-
ered that maintaining a protocol with at least two periods
of rapid pacing and balloon pre-dilatation increased the
potential risk for hemodynamic disturbances. More and
more centers are beginning to avoid this maneuver to
simplify the procedure, since clinical experience of avoid-
ing predilatation has been good. Several clinical trials are
ongoing but so far most centers rely on their individual
experience.
Myocardial hypoperfusion and even circulatory collapse
are rare but serious events after multiple RP periods [12].
TAVI has been associated with the development of acute
renal failure [13–15]. Impaired renal function is often a
component of comorbidity in TAVI candidates. Avoidance
of one period of rapid pacing, by avoiding balloon predila-
tation, shortens the procedure and reduces the risk for
temporary circulatory failure. In patients at risk for
renal failure it would seem beneficial to omit unneces-
sary maneuvers that could lead to temporary renal hypo-
perfusion. It is reasonable to believe that the modified
procedure with just one RP period should reduce this risk.










Approach TF/TA (n) 26/4 24/6 ns
Procedure time (min) 68 (35–210) 80 (30–360) ns
Fluoroscopy (min) 22 (6–45) 27 (9–84) ns
No contrast (n) 17 10 ns
Contrast ml (n) 13 20
Mean (range) 38 (20–60) 42 (20–163) ns
Minor vasc. complic. (n) 2 4 ns
Major vasc. complic. (n) 2 1 ns
Pericardial bleeding (n) 2 2 ns
Sternotomi + hemostasis 2 0 ns
ECC (n) 1 1 ns
Crossover 0 2 ns
Valve embolization 1 0 ns
Valve dysfunction 0 1 ns
PVL = 0, (n) 9 5 ns
PVL median (range) 0.5 (0–1) 0.5 (0–1) ns
No of pacing 0 pacing n = 1a 1 pacing n = 1a Pacing:
1 pacing n = 28 2 pacing n = 21 NBD vs BD
2 pacing n = 1 3 pacing n = 8 P < 0,001
aSpontaneous drop in BP with Sapien™ in native valve. TF transfemoral, TA
transapical, ECC extracorporeal circulation, PVL paravalvular leakage (0.5 = trace,
1 = mild), NBD no balloon dilatation, BD balloon dilatation
Table 3 One-month follow-up data








Vmax m/s 2.1 (1.4–2.8) 1.9 (1.3–2.9) ns
Mean gradient mmHg 10 (3–17) 9 (4–17) ns
PVL = 0, (n) 9 3 ns
PVL median (range) 0.5 (0–1) 0.5 (0–1) ns
Gastric bleeding 0 1 ns
Acute kidney injury (n) 0 0 ns
Conduction disturb. (n) 1 1 ns
PPM after procedure 1 0 ns
Stroke (n) 1 2 ns
Death (n) 1 2 ns
Vmax maximum upstroke velocity, PVL paravalvular leakage (0.5 = trace, 1 =
mild) PPM permanent pacemaker
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The potential benefits of avoiding use of the predilatation
balloon include less manipulation of the aorta and the LV
outflow tract. Theoretically this should reduce the risk of
emboli and conduction disturbances. If the balloon is used
for gaging size or for other purposes then this modified
procedure clearly has a drawback. We have now used it
routinely in over 200 patients and have had two cases
where we had real problems passing the native valve, and
had to use a lasso wire to support the nosecone. In 1 case
we had to pre-dilate before the stent valve passed the
native valve. Expansion of the stent has never been a
problem.
In this series of 60 patients we had two patients requir-
ing emergency cardiac surgery for pericardial bleeding due
to guidewire perforation of the left ventricle. In one fur-
ther patient we had to use temporary ECC to support the
patient while suturing the perforation. Three major vascu-
lar complications needed endovascular intervention.
These six patients all recovered and were survivors at the
1-month follow-up illustrating the importance of heart
team cooperation during TAVI.
Based on our experience with guidewire perforation,
we have replaced the stiff guidewire with a soft wire
through the delivery system when reaching the ascend-
ing aorta [16].
This atraumatic wire can be used when balloon predi-
latation is avoided. The soft wire is passed through the
stenosis into the left ventricle and is used as support for
final positioning of the stent valve. More than one hun-
dred patients have been treated this way without any
pericardial bleeding [16].
Limitation and strength
The relatively small sample size does not have the power
to analyse long-term clinical outcome. The strength of
the study is its design, where all patients over a period
of one year coming for TAVI due to native AS were in-
cluded and randomized to balloon pre-dilatation or not.
Conclusion
TAVI can be performed safely without balloon predilata-
tion and without compromising the early hemodynamic
outcome of the procedure. The reduction in the number of
pacing periods required may be beneficial for the patient.
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